It seems to me that almost everyone is missing the point about this
non-event. I will try again to convey the points which are really
irritating me.
1/ SmithKline Beecham have made NO major breakthrough.
2 SmithKline Beecham have simply re-stated what we have all known for the
past 5 years: that the Dopamine Agonists from Permax on are capable of
acting like dopamine to the nervous system, without increasing the
risk of dyskinesia. (My tablet strategy has been based on this fact
for the last 5 years.
3/ I admit to a grudging respect at SKB's nerve at wrapping the package
so that it fools (apparently) just about everyone at the conference.
4/ Alternatively (and very scary) - it may be that SKB really believed
the results of their 'research'. Could this be true? . The bottom
line seems to be that SKB have fooled a convention-hall full of
specialists, or they have fooled a convention-hall full of specialists
AND themselves. (And if this sounds like the famous old question
'Have you stopped beating your wife?' - GOOD!)
--
Brian Collins <[log in to unmask]>
